

研究成果目錄：(一)

(A). SCIE 期刊論文 (Publication in Science Citation Index Expanded, SCIE)

1. To KY, Lai EM, Lee LY, Lin TP, Hung CH, **Chen CL**, Chang YS, Liu ST. Analysis of the gene cluster encoding carotenoid biosynthesis in *Erwinia herbicola* Eho13. *Microbiol* 1994;140: 331–9. (IF: 2.84)
2. Chang LK, **Chen CL**, Chang YS, Tschen JSM, Chen YM, Liu ST. Construction of Tn917ac1, a transposon useful for mutagenesis and cloning of *Bacillus subtilis* genes. *Gene* 1994;150: 129–34. (IF: 2.871)
3. **Chen CL**, Chang LK, Chang YS, Liu ST, Tschen JSM. Transposon mutagenesis and cloning of the genes encoding the biosynthesis of fengycin. *Mol Gen Genet* 1995;248:121–5. (IF: 2.635; R/C=75/158 , Genetics & Heredity)
4. Lin GH, **Chen CL**, Tschen JSM, Tsai SS, Chang YS, Liu ST. Molecular cloning and characterization of fengycin synthetase gene *fenB* from *Bacillus subtilis*. *J Bacteriol* 1998;180:1339–41. (IF: 3.825; R/C=29/114 , Microbiology)
5. Lin TP, **Chen CL**, Chang LK, Tschen JSM, Liu ST. Functional and transcriptional analyses of a fengycin synthetase gene *fenC* from *Bacillus subtilis*. *J Bacteriol* 1999;181:5060–7. (IF: 3.825; R/C=29/114 , Microbiology)
6. Poon KKH, **Chen CL**, Wong SL. Roles of glucitol in the GutR mediated transcription activation process in *Bacillus subtilis*. Tight binding of GutR to its binding site. *J Biol Chem* 2001;276:9620–5. (IF: 4.773; R/C= 66/290 , Biochemistry & Molecular Biology)
7. Murashima K, **Chen CL**, Kosugi A, Tamaru Y, Doi RH, Wong SL. Heterologous production of *Clostridium cellulovorans engB*, using protease-deficient *Bacillus subtilis*, and preparation of active recombinant cellulosomes. *J Bacteriol* 2002;184:76–81. (IF : 3.825; R/C=29/114 , Microbiology)
8. Lin TP, **Chen CL**, Fu HC, Wu CY, Lin GH, Huang SH, Chang LK, Liu ST. Functional analysis of fengycin synthetase FenD. *Biochimica et Biophysica Acta* 2005;1730:159–64. (IF: 5.000; R/C=56/290, Biochemistry & Molecular Biology)
9. **Wu CY[#]**, **Chen CL[#]**, Wu IC, Lee YS, Liu ST. Fengycin synthetase complex in *Bacillus subtilis* F29-3. *J Biol Chem* 2007;282:5608–16 (IF: 4.773; R/C= 66/290 , Biochemistry & Molecular Biology) ([#] : Chen and Wu are equally contributed)
10. **Chen CL**, Wu XC, Tjia WM, Wang CLC, Lohka M J, Wong SL. Development of a LytE-based high-density surface display system in *Bacillus subtilis*. *Microbial Biotechnol* 2008;1: 177–90. (IF: 4.857; R/C 22/162=13.58% , Biotechnology & Applied Microbiology)
11. Chiou CS, Lin JM, Chiu CH, Chu CH, Chen SW, Chang YF, Weng BC, Tsay JG, **Chen CL**, Liu CH, Chu C. Prevalent *Salmonella* serogroups and serovars and multi-drug resistance-associated clonal dissemination in serogroup C1 *Salmonella enterica* serovars Braenderup, not Bareilly. *BMC Microbiol* 2009;9:264. (IF: 2.98; ranking: 38/107=35.5%)

12. **Chen CL**, Wang CY, Chu C, Su LH, Chiu CH. Functional and molecular characterization of pSE34 encoding a type IV secretion system in *Salmonella enterica* serotype Enteritidis phage type 34. *FEMS Immunol Med Microbiol* 2009;57:274–83. (IF: 2.554; 55/119=46.2%, Microbiology) (currently named Pathogens and Disease)
13. Chiu CH, Lee HY, Liu SY, Tseng LY, **Chen CL**, Su LH. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in *Acinetobacter baumannii* in Taiwan. *Int J Antimicrob Agents* 2010;35:382–6. (IF: 4.259; R/C 12/70=17.1% , Infectious Diseases)
14. Su LH, Teng WS, **Chen CL**, Lee HY, Li HC, Wu TL, Chiu CH. Increasing ceftriaxone resistance in salmonellae, Taiwan. *Emerging Infectious Diseases* 2011;17:1086–90. (IF: 7.327; R/C 3/70=4.3% , Infectious Diseases)
15. Ye J, Su LH, **Chen CL**, Hu S, Wang J, Yu J, Chiu CH. Analysis of pSC138, the multidrug resistance plasmid of *Salmonella enterica* serotype Choleraesuis SC-B67. *Plasmid* 2011;65:132–40. (IF: 1.760; 99/146=67.8% , BIOCHEMISTRY & MOLECULAR BIOLOGY)
16. **Lee HY[#]**, **Chen CL[#]**, Wang SB, Su LH, Chen SH, Liu SY, Wu TL, Lin TY, Chiu CH. Imipenem heteroresistance induced by imipenem in multidrug-resistant *Acinetobacter baumannii*: mechanism and clinical implication. *Internat J Antimicrob Agent* 2011;37:302–8. (IF: 4.259; R/C 12/70=17.1% , Infectious Diseases). (Chen CL and Lee HY are equally contributed)
17. **Chen CL**, Su LH, Chiu CH. Transcription modulation of gene expression in *Salmonella enterica* serotype Choleraesuis by sub-inhibitory concentrations of ciprofloxacin. *Food Res Int* 2012;45:973–7. (IF: 3.050; R/C 14/123=11.4% , FOOD SCIENCE & TECHNOLOGY)
18. Lee HY, Chang RC, Su LH, Liu SY, Wu SR, Chuang CH, **Chen CL** and Chiu CH. Wide-spread of Tn2006 in an AbaR4-type resistance island among carbapenem-resistant *Acinetobacter baumannii* clinical isolates in Taiwan. *Int J Antimicrob Agents* 2012;40:163–7. (IF: 4.296; R/C 14/78=17.95%, Infectious Diseases)
19. Tsai MH, Wu SR, Lee HY, **Chen CL**, Lin TY, Huang YC and Chiu CH. Recognition of mechanisms involved in bile resistance important to halting antimicrobial resistance in nontyphoidal *Salmonella*. *Int J Antimicrob Agents* 2012;40:151–7. (IF: 4.296; R/C 14/78=17.95% Infectious Diseases)
20. Chen SY, Tsai CN, **Chen CL**, Chao SC, Lee YS, Lai MW, Chen CC, Huang WL, and Chiu CH. Severe viral gastroenteritis in children after sub-optimal rotavirus immunization in Taiwan. *Pediatr Infect Dis J* 2013 Dec;32(12):1335–9. (IF: 2.723; 19/117=16.23%, Pediatrics)

21. Fan NC, Chen HH, **Chen CL**, Ou LS, Lin TY, Tsai MH, Chiu CH. Rise of community-onset urinary tract infection caused by extended-spectrum β -lactamase-producing *Escherichia coli* in children. *J Microbiol Immunol Infect* 2014 Oct;47(5):399–405. (IF: 2.973; 50/125=40.0%/Microbiology)
22. Huang YK, Ko PJ, **Chen CL**, Tsai FC, Wu CH, Lin PJ and Chiu CH. Therapeutic opinion on endovascular repair for mycotic aortic aneurysm. *Ann Vasc Surg* 2014;28:579–89. (IF: 1.170; 121/198=61.11%, Surgery)
23. Huang YK, Chu C, Wu CH, **Chen CL***, Chiu CH*. Evaluation of Gram-negative bacterial infection by a stable and conjugative bioluminescence plasmid in a mouse model. *J Biomed Sci* 2014 Aug; 21(1):78. (IF: 2.935; 45/124=36.29%; Medicine, Research & Experimental) (*: corresponding author).
24. Huang YK, **Chen CL**, Lu MS, Tsai FC, Lin PJ, Wu CH, Chiu CH. Clinical, microbiological and outcome analysis of mycotic aortic aneurysm: the role of endovascular repair. *Surg Infect (Larchmt)* 2014;15(3):290–8. (IF: 1.448; 103/198=52.02%, Surgery)
25. Lee HY, **Chen CL**, Wu SR, Huang CW, Chiu CH. Risk factors and outcome analysis of *Acinetobacter baumannii* complex bacteremia in critical patients. *Critical Care Medicine*. 2014;42:1081–8. (IF: 6.312; 4/27=14.81%, Critical Care Medicine)
26. Wang YH, Chen HM, Yang YH, Yang TH, Teng CH, **Chen CL**, Chu C, Chiu CH. Clinical and microbiological characteristics of recurrent group B streptococcal infection among non-pregnant adults. *Int J Infect Dis* 2014 Sep;26:140–5. (IF: 2.330; 44/70=62.9%, Infectious Diseases)
27. Tsai MH, Wu TL, Su LH, Lo WL, **Chen CL**, Liang YH, Chiu CH. Carbapenem-resistant-only *Pseudomonas aeruginosa* infection in patients formerly infected by carbapenem-susceptible strains. *Int J Antimicrob Agents* 2014 Dec; 44:541–545. (IF: 4.296; R/C 14/78=17.95% , Infectious Diseases)
28. Wang YH, **Chen CL**, Hou JN, Wang YR, Lin TY, Wang MH, Yang TH, Chu C, Chiu CH. Serotype distribution and resistance genes associated with macrolide and fluoroquinolone resistance in *Streptococcus agalactiae* isolates from a hospital in Southern Taiwan. *Biomed J* 2015;38:215–20. (IF: 3.697)
29. Tsai MH, Huang SH, **Chen CL**, Chiu CY, Hua MC, Liao SL, Yao TC, Lai SH, Yeh KW, Wang MP, Huang JL. Pathogenic bacterial nasopharyngeal colonization and its impact on respiratory diseases in the first year of life the patch birth cohort study. *Pediatr Infect Dis J* 2015;34:652–8 (IF: 2.723; 19/117=16.23%, Pediatrics).
30. Chen SY, Feng Y, Chao HC, Lai MW, Huang WL, Lin CY, Tsai CN, **Chen CL**, Chiu CH. Emergence in Taiwan of novel norovirus GII.4 variants causing acute gastroenteritis and intestinal hemorrhage in children. *J Med Microbiol* 2015; 64:544–50. (IF: 2.265; 72/123=58.54%, Microbiology)
31. Wei SH, Chiang CS, **Chen CL**, Chiu CH. Pneumococcal disease and use of pneumococcal

vaccines in Taiwan. *Clin Exp Vaccine Res* 2015;4:121–9. (IF: 3.63)

32. Lee HY, **Chen CL**, Liu SY, Yan YS, Chang CJ, Wu CT, Chiu CH. Impact of molecular epidemiology and reduced susceptibility to glycopeptides and daptomycin on outcomes of patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *PLoS One* 2015;10:e0136171. (IF: 3.234; 8/56=14.3%, Multidisciplinary Sciences)
33. **Feng Y[#], Chen CL[#], Chen TH[#]**, Liang YH, Chen HL, Lin CY, Chiu CH. Application of next generation sequencing to study ascitic microbiome in cirrhotic patients with or without spontaneous bacterial peritonitis. *J Microbiol Immunol Infect* 2015; 48:504–9. (IF: 2.973; 50/125=40.0%/Microbiology) (**#: first authors, equally contributed**)
34. Lee HY, Huang CW, **Chen CL**, Wang YH, Chang CJ, Chiu CH. Emergence in Taiwan of novel imipenem-resistant *Acinetobacter baumannii* ST455 causing bloodstream infection in critical patients. *J Microbiol Immunol Infect* 2015;48:588–96.(IF: 2.973; 50/125=40.0%/Microbiology)
35. Wu CT, Lee HY, **Chen CL**, Chiu CH. High prevalence and antimicrobial resistance of urinary tract infection isolates in febrile young children without localizing signs in Taiwan. *J Microbiol Immunol Infect* 2016;49:243–8. (IF: 2.973; 50/125=40.0%/Microbiology)
36. Wu CT, Lee HY, **Chen CL**. A near-fatal case of invasive pneumococcal disease in a vaccinated child. *Pediatr Neonatol* 2016;57:76–8. (IF: 1.773; 73/121: 64.46%, Pediatrics)
37. Yang WC, Chan OW, Wu TL, **Chen CL**, Su LH, Chiu CH. Development of ceftriaxone resistance in *Salmonella enterica* serotype Oranienburg during therapy for bacteremia. *J Microbiol Immunol Infect* 2016;49:41–5. (IF: 2.973; 50/125=40.0%/Microbiology)
38. Feng Y, Ruan Z, Shu J, **Chen CL**, Chiu CH. A glimpse into evolution and dissemination of multidrug-resistant *Acinetobacter baumannii* isolates in East Asia: a comparative genomics study. *Sci Rep* 2016;6:24342. (IF: 5.578; 5/57=8.77%; Multidisciplinary Sciences)
39. Kung YH, Hsieh YF, Weng YH, Lien RI, Luo J, Wang Y, Huang YC, **Chen CL**, Chen CJ. Risk factors of late-onset neonatal sepsis in Taiwan, a matched case-control study. *J Microbiol Immunol Infect* 2016;49:430–5. (IF: 2.973; 50/125=40.0%/Microbiology)
40. Wang PL, Chen SY, Tsai CN, Chao HC, Lai MW, Chang YJ, **Chen CL**, Chiu CH. Complicated norovirus infection and assessment of severity by a modified Vesikari disease score system in hospitalized children. *BMC Pediatr.* 2016;16:162. (IF: 1.813; 45/120= 37.5%, Pediatrics)
41. Janapatla RP, Su LH, Chen HH, Chang HJ, Tsai TC, Chen PY, **Chen CL**, Chiu CH. Epidemiology of culture-confirmed infections of *Streptococcus pneumoniae* (2012-2015) and nasopharyngeal carriage in children and households in Taiwan (2014-2015). *J Med Microbiol* 2017;66:729–36. (IF: 2.265; 72/123=58.54%, Microbiology)
42. Lee HY, **Chen CL**, Wu CT. Foreign body mimicking a granuloma in the ear in an asymptomatic child. *Pediatr Neonatol* 2017; 58: 289–90. (IF: 1.773; 70/120=58.33%, Pediatrics)
43. Wu CT, Hsia SH, **Chen CL**, Lee HY. Acute Fatal Alcohol Intoxication in a 3-Day-Old Neonate. *Pediatr Neonatol* 2017;58:278–80. (IF: 1.773; 70/120=58.33%, Pediatrics)
44. Wu CT, **Chen CL**, Lee HY, Chang CJ, Liu PY, Li CY, Liu MY, Liu CH. Decreased antimicrobial resistance and defined daily doses after implementation of a clinical culture-guided antimicrobial stewardship program in a local hospital. *J Microbiol Immunol Infect* 2017;50:846–56. (IF: 2.973; 50/125=40.0%/Microbiology)

45. Chang YC, Lee HY, Huang JL, Chiu CH, **Chen CL**, Wu CT. Risk factors and outcome analysis in children with carbon monoxide poisoning. *Pediatr Neonatol* 2017;58:171–7. (IF: 1.319; 70/120: 58.33%, Pediatrics)
46. Chang YJ, Chao HC, **Chen CL**, Chen SY, Yan DC, Tsai MH. C-reactive protein may predict the recurrence of appendicitis in children formerly with appendiceal mass after successful non-operative treatment. *Pediatr Neonatol* 2017;58:350–4 (IF: 1.773; 53/120=44.16%, Pediatrics)
47. Chang YJ, Yan DC, Lai JY, Chao HC, **Chen CL**, Chen SY, Tsai MH. Strangulated small bowel obstruction in children. *J Pediatr Surg* 2017;52:1313–7. (IF: 1.733; 86/200=43.0%, Surgery; 50/120=41.67%, Pediatrics)
48. Chia JH, Feng Y, Su LH, Wu TL, **Chen CL**, Liang YH, Chiu CH. *Clostridium innocuum* is a significant vancomycin-resistant pathogen that may cause extraintestinal clostridial diarrhoea. *Clin Microbiol Infect.* 2017;23:560–6. (IF: 5.394; 7/72=9.72%, Infectious Diseases)
49. Feng Y, Chen HL, Chen CJ, **Chen CL**, Chiu CH. Genome Comparisons of Two Taiwanese Community-Associated Methicillin-Resistant *Staphylococcus aureus* ST59 Clones Support the Multi-Origin Theory of CA-MRSA. *Infect Genet Evol* 2017;54:60–5. (IF: 2.885, 36/84=42.85%, Infectious Diseases).
50. Lee HY, Wu TL, Su LH, Li HC, Janapatla RP, **Chen CL**, Chiu CH. Invasive pneumococcal disease caused by ceftriaxone-resistant *Streptococcus pneumoniae* in Taiwan. *J Microbiol Immunol Infect* 2018;51:500–9. (IF: 2.094; 50/125=40.0%/Microbiology)
51. Lee HY, Hsu SY, Hsu JF, **Chen CL**, Wang YH, Chiu CH. Risk factors and molecular epidemiology of *Acinetobacter baumannii* bacteremia in neonates. *J Microbiol Immunol Infect* 2018 Jun;51(3):367–376 (IF: 2.973; 50/125=40.0%/Microbiology)
52. Lee HY, **Chen CL**, Chiu CH. An atlantoaxial rotatory subluxation secondary to a parapharyngeal abscess. *Pediatr Neonatol* 2018;59:423–4. (IF: 1.773; 53/120=44.16%, Pediatrics).
53. Chia JH, Wu TL, Wu TS, **Chen CL**, Chuang CH, Su LH, Chang HJ, Lu CC, Kuo AJ, Lai HC, Chiu CH. *Clostridium innocuum* is a vancomycin-resistant pathogen for antibiotic-associated diarrhea. *Clin Microbiol Infect* 2018;24:1195–9. (IF: 5.396; 7/72=9.72%, Infectious Diseases).
54. **Lo YL[#]**, **Chen CL[#]**, Shen L, Chen YC, Wang YH, Lee CC, Wang LC, Chuang CH, Chiu CH, Chang HY. Characterization of the role of global regulator FliA in the pathophysiology of *Pseudomonas aeruginosa* infection. *Res Microbiol* 2018;169:135–44. (IF: 2.549; 27/83=32.53%, Infectious Diseases) (# : **first authors, contributed equally**)
55. Janapatla RP, **Chen CL**, Hsu MH, Liao WT, Chiu CH. Immunization with pneumococcal neuraminidases NanA, NanB and NanC to generate neutralizing antibodies and to increase survival in mice. *J Med Microbiol* 2018;67:709–23. (IF: 2.265; 72/123=58.54%, Microbiology).
56. Huang CC, Wu PW, **Chen CL**, Wang CH, Lee TJ, Tsai CN, Chiu CH. IL-17A expression in the adenoid tissue from children with sleep disordered breathing and its association with pneumococcal carriage. *Sci Rep* 2018;8:16770 (IF: 4.122; 16/188=8.51%; Multidisciplinary Sciences).
57. Feng Y, Lin E, Zou S, **Chen CL**, Chiu CH. Complete genome sequence of *Salmonella enterica*

- serovar Sendai: serological recombination with *S. Miami* and recent divergence from *S. Paratyphi A*. *BMC Genomics* 2019; 20:398. (IF: 3.501; 48/162=29.6%; Biotechnology & Applied Microbiology)
58. Chang YJ, Hsiao HJ, Hsia SH, Lin JJ, Huang MS, Chung HT, Su WJ, **Chen CL**, Huang YC, Tsai MH. Analysis of Clinical Parameters and Echocardiography as Predictors of Fatal Pediatric Myocarditis. *PLOS ONE* 2019;14:e0214087. (IF: 2.766; 8/56=14.3%, Multidisciplinary Sciences)
 59. Lee HY, Hsiao HL, Chia CY, Cheng CW, Tsai TC, Deng ST, **Chen CL**, Chiu CH. Risk factors and outcomes of *Clostridium difficile* infection in hospitalized patients. *BioMed J* 2019;42:99–106. (IF: 1.723, 235/292=80.5%; Biochemistry & Molecular Biology)
 60. Fu TK, Ng SK, Chen YE, Lee YC, Demeter F, Herczeg M, Borbás A, Chiu CH, Lan CY, **Chen CL**, Chang MDT. Rhamnose binding protein as anti-bacterial agent — Targeting biofilm of *Pseudomonas aeruginosa*. *Marine Drugs* 2019;17:E355. (IF=3.772, 15/61=24.6%, Chemistry, Medical).
 61. Wong MY, Tseng YH, Huang TY, Chiu CH, **Chen CL**, Huang YK. Role of different *Salmonella enterica* serotypes in THP-1 macrophage derived foam cell autophagy and inflammatory response. *Sains Malaysiana* 2019 May;48:2249–56. (IF: 0.565; Q4)
 62. **Hsu JF[#]**, **Chen CL[#]**, Lee CC, Lien R, Chu SM, Fu RH, Chiang MC, Yang CY, Lai MY, Wu IH, Lee CC, Yen YS, Chiu CH. Characterization of group B streptococcus colonization in full-term and late-preterm neonates in Taiwan. *Pediatr Neonatol* 2019 Jun;60:311–7.(IF: 1.773; 87/124: 70.1%, Pediatrics) (# : **First author, equally contributed**).
 63. Lo CW, Liu HC, Lee CC, Lin CL, **Chen CL**, Jeng MJ, Chiu CH. Serotype distribution and clinical correlation of *Streptococcus agalactiae* causing invasive disease in infants and children in Taiwan. *J Microbiol Immunol Infect* 2019 Aug;52:578–84. (IF=2.455; 50/125=40.0%/Microbiology)
 64. Chen CH, Su LH, Li HC, Hsu MH, Wu TL, **Chen CL**, Kuo KC, Chiu CH. Evaluation of the impact of 13-valent pneumococcal conjugate vaccine immunization in children by surveillance of culture-confirmed pneumococcal disease: a prospective clinical microbiological study. *Vaccine* 2019 Aug;37:5147–52. (IF=3.269, 57/136=41.9%, Medicine, Research & Experimental)
 65. Lin SC, Chen HH, Lee WI, **Chen CL**, Chiu CH. Pneumonia and empyema caused by *Methylobacterium* in a patient with X-linked chronic granulomatous disease. *Pediatr Neonatol* 2019 Oct;60:584–6. (IF: 1.773; 73/124=58.9%, Pediatrics).
 66. Chu C, Wong MY, Chiu CH, Tseng YH, **Chen CL**, Huang YK. *Salmonella*-infected aortic aneurysm: investigating pathogenesis using *Salmonella* serotypes. *Pol J Microbiol* 2019 Dec; 68:439–47. (IF: 0.776)
 67. Lee CC, Zhou YL, Hsu JF, **Chen CL**, Lien R, Chiu CH. Clinical and microbiological characteristics of group B *Streptococcus* from pregnant women and diseased infants in intrapartum antibiotic prophylaxis era in Taiwan. *Sci Rep* 2019 Sep 19;9(1):13525. (IF=4.011, 15/69=21.7%, Multidisciplinary Sciences).
 68. Huang CC, Wu PW, Lee TJ, **Chen CL**, Wang CH, Tsai CN, Chiu CH. Differential IL-17A response to *S. pneumoniae* in adenoid tissue of children with sleep disordered breathing and

- otitis media with effusion. *Sci Rep* 2019 Dec 27;9(1):19839. (IF: 4.122; 16/188=8.51%; Multidisciplinary Sciences).
69. Chen HH, Hsu MH, Li HC, **Chen CL**, Janapatla RP, Su LH, Wu TL, Chiu CH. Non-typeable *Streptococcus pneumoniae* infection in a medical center after wide use of pneumococcal conjugate vaccine. *J Microbiol Immunol Infect* 2020 Feb; 53:94–8. (IF: 3.493; 33/93=35.5%/Infectious Diseases).
70. **Chen CL**, Su LH, Janapatla RP, Lin CY, Chiu CH. Genetic analysis of virulence and antimicrobial-resistant plasmid pOU7519 in *Salmonella enterica* serovar Choleraesuis. *J Microbiol Immunol Infect* 2020 Feb;53:49–59. (IF: 3.493; 33/93=35.5%/Infectious Diseases).
71. Cao Q, Chen YC, **Chen CL**, Chiu CH. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. *J Formos Med Assoc* 2020 March; 119:670–3. (IF: 2.844; 35/160=21.9%/Medicine, General & Internal).
72. **Chen CL**, Hou PC, Wang YT, Lee HY, Zhou YL, Wu TS, Janapatla RP, Yang CC. The high mortality and antimicrobial resistance of *Klebsiella pneumoniae* bacteremia in northern Taiwan. *J Infect Dev Ctries* 2020 Apr;14(4):373–9. (Chen CL Hou PC, and Wang YT with equal contribution) (IF: 1.175; 82/87 = 94.25%, Infectious Diseases)
73. Lin HH, Chen HL, Janapatla RP, **Chen CL**, Chiu CH. Hyperexpression of type III secretion system of *Salmonella* Typhi linked to a higher cytotoxic effect to monocyte-derived macrophages by activating inflammasome. *Microbial Pathogens*. 2020 May;146:104222. (IF: 2.581; 79/133=59.40%, Microbiology).
74. Chen YC, Chen HH, Janapatla RP, Düdek A, Hsu MH, **Chen CL***, **Chiu CH***. Thomsen-Friedenreich antigen activation as a predictor for clinical outcome of pediatric patients with invasive pneumococcal disease. *Pediatr Neonatol* 2020 Jun;61:338–42. (IF: 1.773; 53/120=44.16%, Pediatrics). (*: **corresponding author**)
75. Janapatla RP, Hsu MH, **Chen CL**, Wei SH, Yu MJ, Su LH, Lin TY, Chiu CH. Persistence of immunity in children immunized with 13-valent pneumococcal conjugate vaccine and impact on nasopharyngeal carriage. *Thorax*. 2020;75:689–92 (IF: 10.307; 3/88=3.41%, Infectious Diseases)
76. Chang YJ, Feng Y, Chen MC, Su LH, Li HC, Yang HP, Yu MJ, **Chen CL***, Chiu CH*. Highly Antimicrobial-resistant nontyphoidal *Salmonella* from retail meats and clinical impact in children, Taiwan. *Pediatr Neonatol* 2020 Aug;61:432–8. (*: **corresponding author**) (IF: 1.773; 53/120=44.16%, Pediatrics).
77. Chen YW, Huang MZ, **Chen CL**, Kuo CY, Yang CY, Chiang-Ni C, Chen YYM, Hsieh CM, Wu HY, Kuo ML, Chiu CH, Lai CH. PM2.5 impairs macrophage functions to exacerbate pneumococcus-induced pulmonary pathogenesis. *Particle and Fibre Toxicology* 2020;17:37. <https://doi.org/10.1186/s12989-020-00362-2>. (IF:7.546)
78. Tsai MH, Liang YH, **Chen CL**, Chiu CH. Characterization of *Salmonella* resistance to bile during biofilm formation. *J Microbiol Immunol Infect*. 2020 Aug; 53:518–24. <https://doi.org/10.1016/j.jmii.2019.06.003>. (IF: 3.493; 33/93=35.5%/Infectious Diseases).
79. Chen CH, **Chen CL**, Arguedas A, Southern J, Hsiao CC, Chiu CH*. Divergent serotype distribution between children with otitis media and those without in the pneumococcal conjugate vaccine era. *J Microbiol Immunol Infect* 2020;53:1035–8. (IF: 3.493;

33/93=35.5%/Infectious Diseases).

80. Lin HH, Chen HL, Weng CC, Janapatla RP, **Chen CL***, Chiu CH*. Activation of apoptosis by *Salmonella* pathogenicity island-1 effectors through both intrinsic and extrinsic pathways in *Salmonella*-infected macrophages. *J Microbiol Immunol Infect* 2020. <https://doi.org/10.1016/j.jmii.2020.02.008>. (IF: 3.493; 33/93=35.5%/Infectious Diseases) (*: **corresponding author**)
81. Chiang MC, **Chen CL**, Feng Y, Chen CC, Lien R, Chiu CH. *Lactobacillus rhamnosus* sepsis associated with probiotic therapy in an extremely preterm infant: pathogenesis and a review for clinicians. *J Microbiol Immunol Infect* 2020 April. <https://doi.org/10.1016/j.jmii.2020.03.029>. (IF: 3.493; 33/93=35.5%/Infectious Diseases).
82. Chen YC, Cao Q, **Chen CL**, Chiu CH. Reply to letter to the editor: Kawasaki Disease and COVID-19: a pretext for a hot topic. *J Formos Med Assoc* 2021, In press. <https://doi.org/10.1016/j.jfma.2021.01.001>.
83. Hsiao HJ, Wang CJ, Lee CC, Hsin YC, Yau SY, Chen SY, Lo WC, Wu PW, **Chen CL**, Chang YJ. Point-of-care ultrasound may reduce misdiagnosis of pediatric intussusception. *Frontiers in Pediatrics*. 2021. Accepted Jan 09, 2021.
84. **Chen CL**, Anna Dudek, Liang YH, Janapatla RP, Lee HY, Hsu L, Kuo HY, Chiu CH. D-mannose-sensitive pilus of *Acinetobacter baumannii* is associated with biofilm formation and adherence to respiratory tract epithelial cells. *J Microbiol Immunol Infect*. 2020 Nov. (Accepted Jan 27, 2021)

(B). 會議後 SCIE 期刊論文(Conference articles with SCIE)

1. Wu CT, Lee HY, **Chen CL**, Tuan PL, Chiu CH. Abstracts of the 10th international symposium on antimicrobial agents and resistance (ISAAR2015). P2-LBCM001: High prevalence and antimicrobial resistance of urinary tract infection isolates in febrile young children without localizing signs in Taiwan. *Int J Antimicrob Agents* 2015;45 (Supple 2):S137. (IF: 4.296; R/C 14/78=17.95%, Infectious Diseases)
2. Lee HY, Huang CW, Wang YH, **Chen CL**, Chang CJ, Chiu CH. Abstracts of the 10th international symposium on antimicrobial agents and resistance (ISAAR2015). P2-LBEI005: Emergence in Taiwan of novel imipenem-resistant *Acinetobacter baumannii* ST455 causing bloodstream infection in critical patients. *Int J Antimicrob Agents* 2015;45 (Supple 2):S139. (IF: 4.296; R/C 14/78=17.95%, Infectious Diseases)
3. Lee HY, Liu PY, Liu CH, Chang WK, Chiang MC, Li CY, Tseng BW, Liu MY, **Chen CL**, Wu CT. Abstracts of the 7th international congress of the Asia Pacific Society of Infection Control, Taipei, Taiwan. Decreased antibiotic resistance and defined daily dose after implementation of antimicrobial stewardship program in a local hospital in Taiwan. *J Microbiol Immunol Infect* 2015; 48 (Supple 1):S51. (IF: 2.973; 50/125=40.0%/Microbiology)
4. **Chen CL**, Janapatla RP, Chiu CH. Chimeric virulence and antimicrobial-resistant plasmid

pOU7519 in *Salmonella enterica* serovar Choleraesuis. *Int J Antimicrob Agents* 2017; 50 (S2): S29-S68. S53-S54 (S53, OS 8-6). [https://doi.org/10.1016/S0924-8579\(17\)30422-3](https://doi.org/10.1016/S0924-8579(17)30422-3). (IF: 4.307; R/C 14/78=17.95% Infectious Diseases)

5. Lee HY, Hsu SY, **Chen CL**, Wang YH, Chiu CH. Risk factors and molecular epidemiology of *Acinetobacter baumannii* bacteremia in neonates. *Int J Antimicrob Agents* 2017; 50 (S2): S29-S68. (S65, OS 12-3). [https://doi.org/10.1016/S0924-8579\(17\)30422-3](https://doi.org/10.1016/S0924-8579(17)30422-3). (IF: 4.307; R/C 14/78=17.95% Infectious Diseases).
6. Lo CW, Liu HC, Lee CC, Lin CL, **Chen CL**, Jeng MJ, Chiu CH. Serotype distribution and clinical correlation of *Streptococcus agalactiae* causing invasive disease in infants and children in Taiwan. *Int J Antimicrob Agents* 2017; 50 (S2): S69–S278. (S203. PS 358). [http://dx.doi.org/10.1016/S0924-8579\(17\)30423-5](http://dx.doi.org/10.1016/S0924-8579(17)30423-5). (IF: 4.307; R/C 14/78=17.95% Infectious Diseases).

(C). **參與之會議(Oral Presentation in Conference)**

1. **Chen CL**. 2002 年第十八屆生物夏令營 Oral presentation: “A Novel Surface Display on live *Bacillus subtilis*”. (08/21~08/23).
2. **Chen CL**. 2002 年第七屆細菌研討會 Oral presentation: “Cell Wall Binding Proteins and their Fusion Proteins”. (2012/08/26~28).
3. **Chen CL**. 2003 年第八屆細菌研討會 Poster: "Studies on the Acyl Moiety Synthesis of Nonribosomal Lipopeptide Antibiotics", (2003/08).
4. **Chen CL**. 中華民國微生物學會第三十九次會員大會暨學術研討會 Poster: “桿菌屬臨床分離菌株抗真菌作用之分析”(2005/12/25).
5. Kung SS, **Chen CL**, Liu ST. "Involvement of YvsB in nonribosomal peptide synthesis". 國家衛生研究院第三屆細菌基因與致病機轉研討會. pp.22, (2005/05).
6. Kung SS, **Chen CL**, Chien CC, Liu ST, "Studies on the Acyl Moiety Synthesis of Nonribosomal Lipopeptidic Antibiotics," American Society for Microbiology General Meeting, Atlanta., (2005/06).
7. **Chen CL**. 2006 年第十一屆細菌研討會 Poster: Peptide Synthetase Complex Perching on Membrane Is Crucial for Fengycin Production in *Bacillus subtilis*F29-3 (2006/12/25)
8. **Chen CL**. “細菌與宿主細胞之互動”學術研討會。林口長庚兒童醫院 12K 會議室；長庚醫院分子感染症醫學研究中心主辦，行政院國家科學委員會協辦 (March 31, 2007) Oral presentation: “Elements of Cell Death Caused by Type Three Secretion System of *Salmonella* Elements of Cell Death Caused by Type Three Secretion System of *Salmonella*.”
9. **Chen CL**. 國家衛生研究院第五屆細菌基因調控與致病機轉研討會 (April 20-21, 2007) Oral presentation: “Functional and Molecular Characterization of pSE34 Encoding a Type 4 Secretion System in *Salmonella enterica* Serotype Enteritidis Phage Type 34.”
10. **Chen CL**. 107th General Meeting of the American Society for Microbiology, Toronto, ON, Canada. ASM (May 21-25, 2007) Poster: “Characterization of the *Bacillus subtilis* LytE cell wall binding module and the development of a LytE-based surface display system for a high-density surface display of enzymatically active β -lactamase.” a Type 4 Secretion System in *Salmonella enterica* Serotype Enteritidis Phage Type 34.”
11. **Chen CL**. 第三屆沙門氏菌研討會暨其他細菌性人畜共通疾病研討會，地點：國立中興大學獸醫學院 (July 07-08, 2007) Oral presentation: “Functional and Molecular Characterization of pSE34 Encoding
12. **Chen CL**. 第三屆沙門氏菌研討會暨其他細菌性人畜共通疾病研討會，地點：國立中興大學獸醫學院 (July 07-08, 2007) Poster: “Molecular Characterization of Resistance Virulence Plasmids of *Salmonella* Enterica Serovar Choleraesuis.”

13. **Chen CL.** 2007 年第十二屆細菌研討會, Poster: “Molecular Characterization of Resistance Virulence Plasmids of *Salmonella* Enterica Serovar Choleraesuis.” (2007/08/21)
14. **Chen CL.** 中華民國微生物學會第四十一次會員大會暨學術研討會, Poster: 台灣地區鮑氏不動桿菌 imipenem 的抗藥機制 (2007/12/05)
15. Su LH, Chu C, **Chen CL**, Chiu CH, Wu TL, Riley TV, Chang BJ (2007) Molecular characterization of genes conferring cytotoxicity to MDCK cells in *Serratia marcescens*. [B-65] Poster presentation for the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA.
16. **Chen CL**, Chiu CH. 2008 年第十三屆細菌研討會, Poster: “Antimicrobial susceptibility of nontyphoid *Salmonella* clinical isolates in seven Asian countries, 2003-2005“ (2008/08)
17. **Chen CL**, Wang CY, Chiu CH, Chu C, Su LH, Su L. Functional and Molecular Characterization of pSE34 Encoding a Type IV Secretion System in *Salmonella enterica* serotype Enteritidis Phage Type 34. The Infectious Diseases Society of America (IDSA). San Francisco, California. (Oct. 23-28, 2008) Poster
18. **Chen CL**, Wang SB, Chen SH, Chen HL, Liu SY, Chiu ChH. 2009. Mechanism of imipenem resistance in *Acinetobacter baumannii* isolated from Taiwan. 109th General Meeting of the American Society for Microbiology (ASM), Philadelphia, Pennsylvania, USA. ASM, Poster (May 17-21, 2009)
19. 陳易聖, 陳奇良, 邱政洵. 2009 年第十四屆細菌研討會, Poster: “Comparison of *Salmonella* Typhi and *S. Typhimurium* Infection in Mice” (Aug 26-28, 2009)
20. 魏頌讚, 陳奇良, 邱政洵. 2009 年第十四屆細菌研討會, Poster: “Differential transcriptomic profiling of invasive and colonizing strains of methicillin-resistant *Staphylococcus aureus*” (Aug 26-28, 2009)
21. **Chen CL**, Fu YM, Chu C, Chiu CH. 2010. Tracking antimicrobial resistance determinants in the floating genome of *Salmonella enterica* serovar Choleraesuis. 110th General Meeting of the American Society for Microbiology (ASM), San Diego, USA. ASM, Poster (May 23-27, 2010)
22. Lee HY, Wu CT, **Chen CL**, Chuang CH, Lin TY, Chiu CH. Mechanisms of resistance to imipenem and extended-spectrum cephalosporins in *Acinetobacter baumannii* clinical isolates. Present in 20th European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Australia, April 10-13, 2010. Poster
23. **Chen CL**, Fu YM, Chu C, Chiu CH. 2011. Genomic analysis of multidrug-resistant virulence plasmids of *Salmonella enterica* serovar Choleraesuis. 4th Symposium on Antimicrobial Resistance in Animals and the Environment (2011 ARAE), Tours, France. Poster (June 27-29, 2011)
24. Lee HY, Wu SR, **Chen CL**, Chuang CH, Lin TY, Chiu CH. A Comprehensive Study on Mechanisms of Imipenem Resistance in *Acinetobacter baumannii* Clinical Isolates in Taiwan. 21th European Congress of Clinical Microbiology and Infectious Diseases in Milan, Italy, May 7-10, 2011. Poster
25. Lee HY, **Chen CL**, Chuang CH, Lin TY, Chiu CH. Risk Factors for Acquiring Imipenem-resistant *Acinetobacter baumannii* in Taiwan. 21th European Congress of Clinical Microbiology and Infectious Diseases in Milan, Italy, May 7-10, 2011. Poster
26. Lee HY, Wu SR, **Chen CL**, Chuang CH, Lin TY, Chiu CH. Antimicrobial susceptibility and clinical analysis of methicillin-resistant *Staphylococcus aureus* invasive isolates in 2010. 8th International Symposium of Antimicrobial Agents Resistance in Seoul, Korea, April 6-9, 2011. Poster
27. **Chen CL**, Huang YK, Chiu CH. 2012 第十七屆細菌學研討會, Poster: “Development and Application of Bioluminescent Gram-Negative Bacteria” 台灣溪頭 (Aug 29-31, 2012)
28. Lee HY, **Chen CL**, Wu SR, Chiu CH. Clinical and microbiological characteristics of bloodstream infection caused by *Acinetobacter baumannii* complex. 52nd Interscience

Conference on Antimicrobial Agents and Chemotherapy in San Francisco, USA, September 9-12, 2012. Oral

29. Lee HY, Chiu CH, **Chen CL**, Huang CW. Risk factors and outcome analysis of *Acinetobacter baumannii* complex bacteremia in critical patients. The 9th International Symposium on the Biology of *Acinetobacter*, in Cologne, Germany, June 19-21, 2013. Poster
30. Chiu CH, Lee HY, **Chen CL**, Huang CW. Molecular epidemiology of *Acinetobacter baumannii* complex bacteremia in critical patients. The 9th International Symposium on the Biology of *Acinetobacter*, in Cologne, Germany, June 19-21, 2013. Poster
31. **Chen CL**, Huang YK, Chiu CH. (2013, Nov. 7~9) Tracing Gram-Negative Bacteria by a Stable Conjugative Bioluminescence System in Animal Model. 1st International Interscience Conference on Infection and Chemotherapy, in Seoul, Korea. Supported by Chang Gung Memorial Hospital. Poster.
32. 李浩遠、黃致歲、王怡欣、**陳奇良**、張啟仁、邱政洵 (2014, Mar. 22-23) Emergence in Taiwan of novel imipenem-resistant *Acinetobacter baumannii* ST455 causing bloodstream infection in critical patients. 台灣感染症醫學會議. 台灣大學醫學院. Poster.
33. Lee HY, Huang CW, Wang YH, **Chen CL**, Chang CJ, Chiu CH. Emergence in Taiwan of novel imipenem-resistant *Acinetobacter baumannii* ST455 causing bloodstream infection in critical patients. 21th European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain, May 10-13, 2014. Poster
34. Lee HY, Liu PY, Liu CH, Chang WK, Chiang MC, Li CY, Tseng BW, Liu MY, **Chen CL**, Wu CT. Decreased antibiotic resistance and defined daily dose after implementation of antimicrobial stewardship program in a local hospital in Taiwan. The 7th International Congress of the Asia Pacific Society of Infection Control, Taipei, Taiwan. March 26-29, 2015. S51. Poster
35. Wu CT, Lee HY, **Chen CL**, Tuan PL, Chiu CH. High prevalence and antimicrobial resistance of urinary tract infection isolates in febrile young children without localizing signs in Taiwan. 10th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2015) in Incheon, Korea (South). P2-LBCM001. May 13-15, 2015. Poster
36. Lee HY, Huang CW, Wang YH, **Chen CL**, Chang CJ, Chiu CH. Emergence in Taiwan of novel imipenem-resistant *Acinetobacter baumannii* ST455 causing bloodstream infection in critical patients. 10th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2015) in Incheon, Korea (South). P2-LBEI005. May 13-15, 2015. Poster
37. Lee HY, **Chen CL**, Liu SY, Yan YS, Chang CJ, Chiu CH. Impact of Molecular Epidemiology and Reduced Susceptibility to Glycopeptides and Daptomycin on Outcomes of Patients with Methicillin-resistant *Staphylococcus aureus* Bacteremia. ICAAC, San Diego, USA. C-1029.2015. Sep. 17-21, 2015. (Oral presentation)
38. **Chen CL**, Janapatla RP, Chiu CH. Low serum fetuin-A as a biomarker to predict pneumococcal necrotizing pneumonia and hemolytic uremic syndrome in children. 2016 Glyco-Retreat, Great Root Resort, New Taipei City, Taiwan. Apr. 11-13, 2016. (Oral presentation)
39. **Chen CL**, Janapatla RP, Chiu CH. Chimeric virulence and antimicrobial-resistant plasmid

- pOU7519 in *Salmonella enterica* serovar Choleraesuis. The 30th ICC (The 30th International Congress of Chemotherapy and Infection, 2017). S53, OS 8-6. 24-27 Nov. 2017. Taipei, Taiwan. (Oral presentation)
40. Lee HY, Hsu SY, **Chen CL**, Wang YH, Chiu CH. Risk factors and molecular epidemiology of *Acinetobacter baumannii* bacteremia in neonates. The 30th ICC (The 30th International Congress of Chemotherapy and Infection, 2017). S65, OS 12-3. 24-27 Nov. 2017. Taipei, Taiwan. (Oral presentation)
 41. Lo CW, Liu HC, Lee CC, Lin CL, **Chen CL**, Jeng MJ, Chiu CH. Serotype distribution and clinical correlation of *Streptococcus agalactiae* causing invasive disease in infants and children in Taiwan. The 30th ICC (The 30th International Congress of Chemotherapy and Infection, 2017). S203. PS 358. 24-27 Nov. 2017. Taipei, Taiwan. (Poster presentation)
 42. Chuang YC, Yu MJ, **Chen CL**, Chiu CH, Liu SY. Clinical analysis and serotype distribution of non-typhoid *Salmonella* infection in northern Taiwan. 2018 The 33rd Joint Annual Conference of Biomedical Science. CB022. Mar. 24-25, 2018. Taipei, Taiwan. (Poster presentation).
 43. **Chen CL**. Invasive non-typhoidal *Salmonella* infection: epidemiology, antimicrobial resistance and pathogenesis. 24th Bacteriology Conference in 2019. Aug. 15-17, 2019. I-Shou University, Kaohsiung, Taiwan (Oral presentation)
 44. **Chen CL**. Surveillance and transmission mechanism of *Salmonella enterica* infection in humans and food and pet animals. Research Building, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Jun. 12, 2020. (Oral presentation)
 45. **Chen CL**. Coronavirus COVID-19 could be endless!?. Caesar Park Hotel Taipei, Rotary Club of Taipei Wen-Hwa, Taipei, Taiwan. Oct. 06, 2020. (Oral presentation)
 - 46.

(D). 學位論文(Thesis article)

1. **Chen CL**. Biocontrol using anti-fungal antibiotics against plant pathogen *Rhizotonia solani*. Department of Botany, National Chung Hsing University, Taizhong, Taiwan. Thesis of bachelor, 1988.
2. **Chen CL**. Study of fengycin biosynthesis genes of *Bacillus subtilis* F29-3. Department of Botany, National Chung Hsing University, Taizhong, Taiwan. Thesis of master degree, 1990.
3. **Chen CL**. Analysis of fengycin biosynthesis genes of *Bacillus subtilis* F29-3. Department of Botany, National Chung Hsing University, Taizhong, Taiwan. Thesis of PhD degree, 1995.

研究成果目錄：(二)智慧財產權及應用成果

1. 請將個人研究成果分為(1)專利(2)技術移轉(3)著作授權(4)其他等類別，分別填入下列表中。
2. 如所列之研究成果係補助之研究計畫所產生，請填入相關之計畫編號。
3. 填寫順序請依專利期間起始日排列，或技術移轉及著作授權之簽約日期排列。

4.如欄位不足，請自行加印填寫。

(1) 專利 請填入目前仍有效之專利。「類別」請填入代碼：(A)發明專利(B)新型專利。

獲通過之年度	國別	專利/技轉名稱	成果產出歸屬計畫 (專屬或非專屬授權)	專利證書號碼 /發明人	技轉/廠商	專利期限	備註: (A)發明專利(B)新型專利
2012 Sep	美國	Method for tracing Gram-negative bacteria inside animal model using stable and bioluminescence-based expression system (Method) [一種用於老鼠模式中使用穩定自發發光載體表現系統來追蹤革蘭陰性細菌的方法(方法學)]	MOST / NSC-99-2314-B-1 82A-049-MY2/長庚醫療財團法人	Patent number: US 8,263,366 B2/Chiu CH, Chen CL, and Huang YK	無	2011/05/17~2031/05/16	A
2012 Sep	美國	Method for tracing Gram-negative bacteria inside animal model using stable and bioluminescence-based expression system (Sequence) [一種用於老鼠模式中使用穩定自發發光載體表現系統來追蹤革蘭陰性細菌的方法(序列)]	MOST / NSC-99-2314-B-1 82A-049-MY2/長庚醫療財團法人	Patent number: US 8,268,616 B2/Chiu CH, Chen CL, and Huang YK	無	2010/10/01~2030/09/30	A
2013 Jun	大陸	可穩定自發光的細菌質粒及其製備方法	MOST / NSC-99-2314-B-1 82A-049-MY2/長庚醫療財團法人	Patent number: CN102268447 B/邱政洵、陳奇良、黃耀廣	無	2010/06/01~2030/05/31	A
2013 Aug	台灣	革蘭陰性細菌專用之穩定自發發光載體及其製作方法	MOST / NSC-99-2314-B-1 82A-049-MY2/長庚醫療財團法人	Patent number: I414599 /邱政洵、陳奇良、黃耀廣	無	2010/05/21~2030/05/20	A
2015 May	美國	Method of detecting the presence of pneumococcal neuraminidases in <i>Streptococcus pneumoniae</i> -infected samples [一種用於檢定檢體中肺炎鏈球菌感染時神經胺酸酶存在性的方法]	MOST / NSC-100-2314-B-182A-079-MY3/ 長庚醫療財團法人	Patent number: US 9,023,599 B2; Chiu CH, Janapatla RP, Chen CL, Hsu MH, Chen HL, Huang CT, Chang HJ, and Liao WT.	無	Filed: 2013/2/25. Date of patent: May 5, 2015. 2013/2/25~2033/2/24	A
2015 May	美國	Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases (一種使用神經胺酸酶來檢測和避免肺炎鏈球菌感染症的方法)	MOST / NSC-100-2314-B-182A-079-MY3/ 長庚醫療財團法人	Patent number: US 9,040,057 B2; Chiu CH, Janapatla RP, Chen CL, Hsu MH, Chen HL, Huang CT, Chang HJ, and Liao WT.	無	Filed: 2011/09/25 Date of Patent: May 26, 2015 2011/09/25~2031/09/24	A
2015 Sep	台灣	使用肺炎鏈球菌神經胺酸酶作為診斷和預防肺炎鏈球菌感染症之方法	MOST / NSC-100-2314-B-182A-079-MY3/	專利發明號：I482969。邱政洵、Rajendra P. Janapatla、陳奇良、徐美華、陳秀	無	May 1, 2015~Dec. 29, 2031. (申請日：2011/12/20) 2011/12/20~2031/12/19	A

			長庚醫療財團法人	玲、黃忠翠、張欣如、廖婉婷。		
2015 Dec	美國	A method for detection of hemolytic uremicsyndrome and necrotizing pneumonia in children with pneumococcal disease using serum fetuin-A levels as a biomarker (一種使用血清胎球蛋白 A 作為生物標誌物以檢測小孩在肺炎鏈球菌感染時引發溶血性尿毒症及壞死性肺炎疾病的檢測方法)	MOST 104-2320-B-182A -008-/Chang Gung Medical Foundation	Patent No.: US 9,261,504 B1; Chiu CH, Janapatla RP, Chen CL/US patent filing: 2014/09/26.	無	US patent filing: 2014/09/26; Date of Patent: Feb. 16, 2016. A
2016 Apr	台灣	使用血清胎球蛋白 A 作為生物標誌物作為檢測小孩在肺炎鏈球菌感染時引發溶血性尿毒症及壞死性肺炎疾病的檢測方法	MOST 104-2320-B-182A -008-/長庚醫療財團法人	專利發明號：I536017/邱政洵、Rajendra P. Janapatla、陳奇良/台灣專利	無	申請日：2014/09/16 核准日期：2016/04/07 期間：2016/6/1-2034/9/15 A
2016 Jun	大陸	具對抗肺炎鏈球菌感染的蛋白疫苗組成物及檢測樣品中肺炎鏈球菌的方法	長庚醫療財團法人	專利發明號：ZL 2013 1 0089769.0/邱政洵、Rajendra P. Janapatla、陳奇良、徐美華、陳秀玲、黃忠翠、張欣如、廖婉婷	無	申請日：2013/3/20。 申請號：201310089769.0 期間：2013/3/20-2033/3/19 A
2020 Mar	台灣	人源抗腸病毒 71 型單株抗體的製法、產物及其應用	長庚醫療財團法人	專利案號：I 688653。 Inventors: 黃冠穎、陳奇良。		申請號：107103194。 2020/03/21~2038/01/29。 A

(2) 技術移轉

技術名稱	專利名稱	授權單位/技轉廠商	接受單位	合約期間	計畫編號
腸病毒 71 型人源單株抗體	人源抗腸病毒 71 型單株抗體群的製法、產物及其應用	長庚醫療財團法人/高端疫苗生物製劑股份有限公司	專利案號：I 688653。 申請號 109103842。 Inventors: 黃冠穎、陳奇良。	2020/03/21~2038/01/29。	CMRPG3E1471~3

目前績效：(可另紙繕寫)。

(5). 專利申請中

- Inventors: 黃冠穎、陳奇良。Assignee: Chang Gung Memorial Foundation, Linkou branch, Taoyuan, Taiwan。”人源抗腸病毒 71 型單株抗體”。申請號 109103842。2020/02/07。案號：P06626-1。(Taiwan patent application)
- Inventors: 黃冠穎、陳奇良。Assignee: Chang Gung Memorial Foundation, Linkou

branch, Taoyuan, Taiwan。”人源抗腸病毒 71 型單克隆抗體的製法、產物及其應用”。申請號 201810092819.3。2018/01/31~2038/01/30。中國（案號：P10636-CN）。（Mainland China application）

(H). 相關訓練之證書 (License or Certificate) :

- 操作人員輻射安全訓練班結訓 (Operating Personnel Radiation Safety Training Class Training) (93 輻協訓字第 0026)。
- 勞工安全衛生管理監督人員訓練安結訓 (Labor safety and health management
- 生物安全官教育訓練 (Biological safety officer education training) (101 環測訓字第 20086 號合格證書)。
- 勞工安全衛生教育訓練結業證書 (Labor safety and health education training certificate) (勞安管特化字第 11114 號)
- 職業安全衛生在職教育訓練證書 (有害在訓 109 證字第 00715)

(I) 學會會員 (Society):

- 台灣微生物學會 (Taiwan Society of Microbiology)

(L). 執行之計畫

研究計劃主題	編號	主持人類別	研究期限	產出之論文
肺炎鏈球菌 19A 血清型之基因分型及盤尼西林結合蛋白 2B 之基因轉殖及結構分析	CMRPG370551	主持人	2008/06/01~ 2009/12/31	<i>Pediatr Infect Dis J.</i> 2010; 29:467-9. <i>J Microbiol Immunol Infect.</i> 2017 Dec;50(6):846-856 <i>PLoS One.</i> 2013;8:e63210.
應用比較基因體學尋找並分析抗藥性金黃色葡萄球菌在鼻腔移生之機轉	NMRPG476011 (97-2314-B-182A-019-MY3)	主持人	2008/08/31~ 2009/07/31	<i>PLoS One.</i> 2015; 10:e0136171. <i>J Microbiol Immunol Infect.</i> 2016 Jun;49(3):430-5.
沙門氏菌感染所誘導之血管內皮細胞功能喪失在動脈瘤病程中所扮演的角色及動物模式建立	NMRPG380051 98-2314-B-182A-037-	共同主持人(與黃耀廣 醫師合作)	2009/08/01~ 2010/12/31	<i>Surg Infect (Larchmt).</i> 2014;15:290-8.
鮑氏不動桿菌對 imipenem, tigecycline 及 colistin 的抗藥機制研究	NMRPG286011 NMRPG286012 98-2314-B-182A-009-MY2	共同主持人(與蔡明翰醫師合作)	2009/08/01~ 2011/07/31	<i>Int J Antimicrob Agents.</i> 2012;40:163-7.
世系 ST59 型移生性及侵襲性之耐甲氧西林金黃色葡萄球菌的具鑑別性轉錄組圖譜之研究	CMRPG381051 CMRPG381052	主持人	2009/09/01~ 2011/08/31	<i>J Microbiol Immunol Infect.</i> 2016 Jun;49(3):430-5. <i>J Biomed Sci.</i> 2014;21:78.
長庚醫院與聖保祿合作計畫:社區感染綠膿桿菌腸炎及敗血症在嬰兒的致病機轉	SMRPG380031	主持人 (與 莊志賢 醫師合作)	2009/09/01~ 2012/02/29	<i>Gut.</i> 2014;63:736-43.
整合型 Applications of Next-Generation Sequencing Technology on Biomedical Research 子計劃四 — 利用第二代新定序方法重新定序 ST59 型之社區金黃色葡萄球菌	CMRPG390701 CMRPG390702	主持人	2010/04/01~ 2012/03/31	<i>Genome Biol Evol.</i> 2013;5:572-7. <i>J Biomed Sci.</i> 2014;21:78. <i>PLoS One.</i> 2015; 10:e0136171.
沙門氏菌感染所誘導之巨噬細胞(及泡沫細胞)功能變化在感染性主動脈瘤病程中所扮演的角色及動物模式建立 (Suppression of the Inflammatory response by <i>Salmonella</i> in foam cells and its association with the	NMRPG396261 NMRPG396262 99-2314-B-182A-049-MY2	共同主持人(與黃耀廣 醫師合作)	2010/08/01~ 2013/07/31	<i>Surg Infect (Larchmt).</i> 2014;15:290-8. <i>Ann Vasc Surg.</i> 2014;28:579-89.

pathogenesis of mycotic aortic aneurysm)

鮑氏不動桿菌之生物膜與抗藥性機制之關聯性研究	NMRPG4A0031 100-2314-B-182A-049-	共同主持人(與李浩遠醫師合作)	2011/08/01~ 2012/07/31	<i>Crit Care Med.</i> 2014;42:1081-8. <i>Int J Antimicrob Agents.</i> 2012;40:163-7.
沙門氏菌形成生物膜時之調控及相關感應系統	NMRPG2A0031 100-2314-B-182A-062-	共同主持人(與蔡明翰醫師合作)	2011/08/01~ 2012/07/31	<i>Int J Antimicrob Agents.</i> 2012;40:151-7.
Phenol-soluble modulins 在社區型抗藥性金黃色葡萄球菌肺炎的角色	NMRPG4A6011 100-2314-B-182A-025-MY2	共同主持人(與陳志隆醫師合作)	2011/08/01~ 2013/07/31	<i>J Clin Microbiol.</i> 2013;51:2508-14 <i>J Antimicrob Chemother.</i> 2014;69:349-54.
在膽汁影響下傷寒沙門氏菌生物膜形成的調控及相關訊息傳導的機轉	101-2314-B-182A-046-	共同主持人(與蔡明翰醫師合作)	2012/08/01~ 2013/07/31	<i>Int J Antimicrob Agents.</i> 2014;44:541-5.
新型的鮑氏不動桿菌序列型ST455的分子流行病學與致病機轉研究	102-2314-B-182A-023-	共同主持人(與李浩遠醫師合作)	2013/08/01~ 2015/07/31	<i>Crit Care Med.</i> 2014;42:1081-8.
以genetically modified <i>Lactobacillus acidophilus</i> 改善宿主之腸道菌叢:探討調節腸道免疫,及發展口服疫苗之可行性	103-2314-B-182A-038-	共同主持人(與陳建彰醫師合作)	2014/08/01~ 2015/07/31	<i>J Microbiol Immunol Infect</i> 2020 April. https://doi.org/10.1016/j.jmii.2020.03.029 .
沙門氏菌引起泡沫細胞自噬反應(autophagy)及發炎複合體(inflammasome)變化:沙門氏菌感染主動脈瘤致病機轉的線索	103-2314-B-182A-073-MY2	共同主持人(與黃耀廣醫師合作)	2014/08/01~ 2016/07/31	<i>Pol J Microbiol</i> 2019 Dec; 68(4):439-447. <i>Sains Malaysiana.</i> 2019; 48(10): 2249-2256.
沙門氏菌誘導巨噬細胞凋亡的機制及其疾病的擴散	CMRPG3A1111~3	主持人	2011/12/01~ 2015/04/30	<i>J Biomed Sci.</i> 2014;21:78. <i>J Microbiol Immunol Infect.</i> 2016;49:41-5 <i>Sci Rep.</i> 2016 Nov 25;6:37642.
探討肺炎鏈球菌結合型疫苗介入後台灣兒童侵襲性肺炎鏈球菌感染症之流行病學、兒童鼻咽帶菌、及疫苗接種後免疫力之分析	NMRPG3F0041 [MOST 105-3011-F-182A-001-]	共同主持人(與邱政詢醫師合作)	2016/01/01~ 2017/06/30	<i>Thorax</i> 2020 May 22. https://doi.org/10.1136/thoraxjnl-2019-213878 . (IF: 10.307)
以老鼠模式探討肺炎鏈球菌感染後唾液酸醣	[MOST	共同主持人(與	2015/08/01~	<i>Medicine (Baltimore).</i> 2016 Mar;95(13):e3221.

蛋白與神經醯胺酶之角色	104-2320-B-182A-008-]	芮傑達博士合 作)	2016/07/31	
臺灣新生兒乙型鏈球菌的帶菌率、血清型分布及抗藥性	[MOST 104-2314-B-182A-137-]	共同主持人(與 徐任甫醫師合 作)	2015/08/01~ 2016/07/31	<i>Pediatr Neonatol</i> 2019 Jun;60:311-7. <i>J Microbiol Immunol Infect.</i> 2016 Apr;49(2):243-8. <i>J Microbiol Immunol Infect.</i> 2020 Feb;53(1):49-59. <i>Sci Rep.</i> 2016 Nov 25;6:37642. <i>Infect Genet Evol.</i> 2017;54:60-65 <i>Clin Microbiol Infect.</i> 2017;23:560-566. <i>J Infect Dev Ctries</i> 2020 Apr;14(4):373-379.
豬霍亂沙門氏菌抗藥暨毒性質體基因組的變更及其重組機制的探討	CMRPG3D0951	主持人	2014/12/01~ 2016/05/31	<i>J Microbiol Immunol Infect.</i> 2020 Feb;53(1):49-59. <i>Sci Rep.</i> 2016 Nov 25;6:37642.
使用創新發光載體於老鼠模式探討克雷氏菌 K1 血清型肝膿瘍的致病機制	CMRPG3F0341	主持人	2016/01/01~ 2017/06/30	<i>Infect Genet Evol.</i> 2017;54:60-65 <i>Clin Microbiol Infect.</i> 2017;23:560-566. <i>J Infect Dev Ctries</i> 2020 Apr;14(4):373-379.
臺灣正常新生兒及早產兒之乙型鏈球菌的帶菌率、血清型分布及抗藥性	[MOST 105-2314-B-182 -065 -MY2]	共同主持人(與 徐任甫醫師合 作)	2016/08/01~ 2018/07/31	<i>Pediatr Neonatol</i> 2019 Jun;60:311-7. <i>Open Forum Infect Dis</i> 2019;6:ofz447. <i>J Microbiol Immunol Infect.</i> 2020 Feb;53(1):49-59. <i>J Microbiol Immunol Infect.</i> 2020.
沙門氏菌之跨物種間感染、監測與管理機制之研究	PMRPG3G0021 [MOHW106-CDC-C-114-113 702] PMRPG3G0022 [MOHW107-CDC-C-114-123 505] PMRPG3G0023 [MOHW107-CDC-C-114-133 505]	主持人	2017/01/01~ 2019/12/31	<i>J Microbiol Immunol Infect.</i> 2020. https://doi.org/10.1016/j.jmii.2020.02.008 . <i>Pediatr Neonatol.</i> 2020; https://doi.org/10.1016/j.pedneo.2020.03.017 . <i>Emerg Infect Dis</i> 2020 (Revising) <i>Virulence</i> 2020 (submitted) <i>Pediatr Neonatol</i> 2019 Jun;60(3):311-317. https://doi.org/10.1016/j.pedneo.2020.03.017 .
造成嚴重感染的 carbapenem 抗藥鮑氏不動桿菌之基因分型、抗藥與致病機制分析	CMRPG3G0981 CMRPG3G0982	主持人	2017/08/01 ~ 2019/7/31	<i>J Infect Dev Ctries</i> 2020 Apr;14(4):373-379. https://doi.org/10.3855/jidc.11524 .
豐原素生產細菌及豐原素衍生物對抗細菌及生物膜之分析	CMRPG3J1851-2	主持人	2019/12/01 ~ 2021/11/30	<i>J Infect Dev Ctries</i> 2020 Apr;14(4):373-379. https://doi.org/10.3855/jidc.11524 .